Study Condition(s): Rheumatoid Arthritis

A Study of LY3337641 in Participants With Rheumatoid Arthritis (RAjuvenate)

Study Alias: JPDA

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02628028 {{ currentLocaleObject.registryAnchorText }}

Recruiting Recruiting

Study Purpose

The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in adults with rheumatoid arthritis (RA).

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18 years
65 years

Time Commitment

Your participation could last up to 10 weeks for Part A or up to 18 weeks for Part B
  • Participant must have a diagnosis of Rheumatoid Arthritis (RA)
  • Participant in Part B must have had inadequate response, loss of response, or intolerance to at least 1 synthetic OR biologic disease-modifying anti-rheumatic drug (DMARD)
  • Female participant of childbearing potential must test negative for pregnancy and agree not to breastfeed; must also agree to use a reliable method of birth control until 28 days after the last dose of study drug unless post-menopausal, have had your tubes tied, ovaries removed and/or hysterectomy
  • Male participant must agree to use a reliable method of birth control until 2 weeks after the last dose of study drug or have undergone vasectomy
  • Participant must not have received belimumab, natalizumab, or vedolizumab within 6 months prior to entering the study
  • Participant must not have received a live (attenuated) vaccine within 28 days prior to entering the study or plan to receive one during the study
  • Participant must not have known hypogammaglobulinemia
  • Participant must not have active tuberculosis (TB), hepatitis C virus, hepatitis B virus or HIV
  • Participant must not have had lymphoma, leukemia, or any malignancy within the previous 5 years (except for basal cell or squamous skin cancer)

Where to Participate

93 locations are currently available of 93 planned
Invalid Postal Code.
Please re-enter postal code.
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.